• Xavier Belenfant, Wided Tabbi Anani, Mélanie Roland, Marie-Christine Mavel, and Joelle Laederich.
• Hôpital André-Grégoire, service de néphrologie dialyse, 93100 Montreuil-sous-Bois, France. xavier.belenfant@chi-andre-gregoire.fr
• Presse Med. 2012 Mar 1;41(3 Pt 1):304-10.

AbstractThe objectives are to slow the progression of chronic kidney disease (CKD), to take all the cardiovascular risk factors into account, to screen for and treat specific complications and to prepare, if necessary, for renal replacement treatment (transplantation or dialysis). The principal treatment targets are: blood pressure less than 130/80 mmHg and proteinuria less than 0.5 g/day (ratio of proteinuria/creatinuria <50mg/mmol). The first-line treatment to reach these goals is angiotensin conversion enzyme inhibitors (ACE inhibitors), combined with diet and other life style changes. The periodicity of clinical and laboratory assessments depends on the CKD stage, the speed of disease progression and the need to reassess the impact of therapeutic interventions. Comprehensive multidisciplinary management can slow or even stop the progression of CKD and reduce its cardiovascular complications, which are the leading cause of death in these patients.Copyright © 2012. Published by Elsevier Masson SAS.

36 keywords...

hide…